Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression by Laura Gonzalez-Calero et al.
Gonzalez‑Calero et al. Cardiovasc Diabetol  (2016) 15:8 
DOI 10.1186/s12933‑016‑0331‑7
ORIGINAL INVESTIGATION
Urinary alpha‑1 antitrypsin and CD59 
glycoprotein predict albuminuria development 
in hypertensive patients under chronic 
renin‑angiotensin system suppression
Laura Gonzalez‑Calero1, Marta Martin‑Lorenzo1, Fernando de la Cuesta2, Aroa S. Maroto1, 
Montserrat Baldan‑Martin2, Gema Ruiz‑Hurtado3,4, Helena Pulido‑Olmo3, Julian Segura3, Maria G. Barderas2, 
Luis M. Ruilope3*, Fernando Vivanco1,5 and Gloria Alvarez‑Llamas1*
Abstract 
Background: Hypertension is a multi‑factorial disease of increasing prevalence and a major risk factor for cardio‑
vascular mortality even in the presence of adequate treatment. Progression of cardiovascular disease (CVD) occurs 
frequently during chronic renin‑angiotensin‑system (RAS) suppression, and albuminuria is a marker of CV risk. High 
prevalence of albuminuria in treated hypertensive patients has been demonstrated, but there are no available mark‑
ers able to predict evolution. The aim of this study was the identification of novel indicators of albuminuria progres‑
sion measurable in urine of diabetic and non‑diabetic patients.
Methods: 1143 hypertensive patients under chronic treatment were followed for a minimum period of 3 years. 
Among them, 105 diabetic and non‑diabetic patients were selected and classified in three groups according to 
albuminuria development during follow‑up: (a) patients with persistent normoalbuminuria; (b) patients develop‑
ing de novo albuminuria; (c) patients with maintained albuminuria. Differential urine analysis was performed by 2D 
gel electrophoresis (2D‑DIGE) and further confirmed by liquid chromatography‑mass spectrometry. Non‑parametric 
statistical tests were applied.
Results: CD59 glycoprotein and alpha‑1 antitrypsin (AAT) resulted already altered in patients developing albuminuria 
de novo, with a similar response in those with maintained albuminuria. A prospective study in a sub‑group of nor‑
moalbuminuric patients who were clinically followed up for at least 1 year from urine sampling, revealed CD59 and 
AAT proteins significantly varied in the urine collected from normoalbuminurics who will negatively progress, serving 
as predictors of future albuminuria development.
Conclusions: CD59 and AAT proteins are significantly altered in hypertensive patients developing albuminuria. 
Interestingly, CD59 and AAT are able to predict, in normoalbuminuric individuals, who will develop albuminuria in the 
future, being potential predictors of vascular damage and CV risk. These findings contribute to early identify patients 
at risk of developing albuminuria even when this classical predictor is still in the normal range, constituting a novel 
strategy towards a prompt and more efficient therapeutic intervention with better outcome.
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Background
Cardiovascular disease continues being the first cause of 
death even in the presence of adequate treatment, where 
renin-angiotensin-system (RAS) blockade is fundamen-
tal and has to be chronically maintained. Albuminuria 
is a marker of cardiovascular damage, and maintenance 
of albuminuria or development of de novo albuminuria 
during adequate treatment is a marker of cardiovascu-
lar disease progression and potentially of renal function 
worsening [1–4]. In fact, worse clinical outcomes have 
been observed in individuals with high albuminuria and 
preserved estimated glomerular filtration rate (eGFR) 
than for those showing reduced eGFR and no albuminu-
ria [5].
The ability of renin-angiotensin system (RAS) sup-
pression to reduce albuminuria has been amply dem-
onstrated. It is well established that RAS suppression is 
required in patients with increased amounts of albumin 
in urine with the double objective of facilitating blood 
pressure (BP) control while diminishing the amount of 
albumin in urine beyond the limit obtained by BP drop 
[6, 7]. However, during chronic suppression of RAS pro-
gression of cardiovascular damage is very frequent, and 
here again the presence of albuminuria is an indicator 
of bad prognosis. Our group and others have shown the 
development of albuminuria in patients receiving chronic 
suppression of the RAS [3, 8]. In our experience develop-
ment of new-onset high albuminuria has been observed 
in 16.1 % of normoalbuminuric patients during a follow-
up of 3 years [3]. The development of new-onset albumi-
nuria in our patients under chronic RAS suppression is 
accompanied by a characteristic pattern of increased oxi-
dative stress [9]. The need to discover predictors of the 
development and the ulterior worsening of CV and renal 
prognosis is required [10, 11].
Omics-based approaches are powerful strategies to 
investigate novel markers of disease aimed to improve 
current diagnosis, predict patient prognosis or define 
novel therapeutic targets, which have been successfully 
applied in kidney pathology [12–15]. Urine has been 
investigated, in particular, to study renal physiology and 
kidney diseases, as it represents a combination of both 
plasma ultrafiltrate and urinary tract proteins, includ-
ing glomerular filtered plasma proteins and soluble pro-
teins secreted by epithelial cells and microvesicles as 
exosomes. Complementary to plasma or serum, urine 
is an ideal non-invasive biofluid, quite stable and sub-
ject to minimal degradation in the bladder and urinary 
tract, and a rich source of potential markers of disease. 
Urine composition not only reflects normal kidney func-
tion but also contains specific kidney produced proteins 
which may be altered in response to underlying physi-
opathology [16]. Our group and others have investi-
gated urine in the search for novel molecular targets of 
potential use in the clinical setting from a diagnosis or 
prognosis point of view in the context of cardiovascu-
lar disease [17]. Albuminuria is also a predictor of renal 
damage and urinary omics has also been applied to dia-
betic nephropathy [18], acute kidney injury [19], and 
chronic kidney disease [20] among others [21]. Here, 
we applied first differential proteomic analysis to inves-
tigate early urinary changes in albuminuria progression 
in non-diabetic hypertensive patients with chronically 
RAS suppression. A highly sensitive, specific and high-
throughput methodology was additionally implemented 
to confirm and quantify most dramatic molecular 
changes taking place in urine and here identified, as pre-




Patient selection and classification was previously 
described in an initial paper showing the development 
of high albuminuria in patients during chronic RAS sup-
pression [3]. Briefly, 1143 patients were followed for a 
minimum period of 3 years with visits to the Hyperten-
sion Unit, Hospital Universitario 12 de Octubre, Madrid, 
at least, every 6 months. After that, the patients contin-
ued with their annual revisions. One hundred and five 
hypertensive patients (66 non diabetic and 39 diabetic) 
with or without albuminuria were recruited between Jan-
uary 2012 and June 2013. Patients were classified accord-
ing to high albuminuria development during follow-up in 
3 groups: (a) patients with persistent normoalbuminuria 
(N); (b) patients developing de novo albuminuria during 
follow-up (dnHA); (c) patients with maintained albumi-
nuria during follow-up (MHA). A control group of urine 
samples from healthy individuals (C) was also included to 
evaluate potential differences attributed to hypertension 
itself. Details about specific cohorts included in the dis-
covery or confirmation phase are given in the following 
sections. Patients with renal diseases as potential cause 
of hypertension were excluded. The study was conducted 
according to recommendations of Declaration of Helsinki 
and approved by the Ethics Committee of the Hospital 12 
de Octubre. Informed consent was requested from sub-
jects prior to inclusion in the study.
Keywords: Albuminuria, Alpha‑1 antitrypsin, Cardiovascular risk, CD59, Hypertension, Urine, Markers
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Differential proteomics analysis (discovery phase)
Individual urine samples from a total of 15 patients and 
six healthy subjects were used in the discovery phase 
[5–6 individual samples were pooled per group (C, N, 
dnHA and MHA)]. All subjects were non-diabetic to 
avoid diabetes as a background pathology in this first 
discovery phase. Table  1 compiles baseline character-
istics of patients included in this phase, showing per-
fectly matched groups with no significant differences in 
any of the variables among patient groups (Additional 
file 1: Table S1 shows additional information of baseline 
patients’ medication). Differential proteomics analysis 
in urine was performed by 2D-DIGE (GE Healthcare) as 
previously published [22–24]. Gels were scanned using 
a Typhoon 9400 Variable Mode Imager (GE Healthcare) 
and spot maps (gel images) were processed, analyzed 
and compared using the DeCyder Differential Analysis 
Software version 6.5 (GE Healthcare). An ANOVA test 
was performed with the expression data of each spot. 
Differential proteins were tryptic digested and identi-
fied in a MALDI-TOF/TOF mass spectrometer 4800 
plus Proteomics Analyzer (Applied Biosystems. MDS 
Sciex, Toronto, Canada) with 4000 Series Explorer™v 3.5 
Software (ABSciex) as previously described [25] with a 
probability score greater than the one fixed by Mascot as 
being significant (p value <0.05).
Mass spectrometry‑based analysis in a confirmation cohort 
(validation phase)
As previously published by our group and others [17, 
18, 26] we used the SRM-LC-MS/MS methodology to 
confirm differential proteins identified in the discovery 
phase. For such purpose, we collected urine samples from 
a different individuals’ cohort to that used in the discov-
ery phase composed by 90 patients (39 diabetic and 51 
non-diabetic) and 18 healthy subjects. Table  2 compiles 
the baseline characteristics of this validation cohort 
(Additional file  1: Table S2 shows additional informa-
tion of baseline patients’ medication). The three groups 
are comparable with marginal differences for total cho-
lesterol, HDL cholesterol and uric acid. In brief, urinary 
proteins were tryptic digested and analyzed in a 6460 
triple quadrupole mass spectrometer on-line connected 
to nano-chromatography (1200 Series, Agilent Technolo-
gies) in a Chip-format configuration (ChipCube interface, 
ProtID Zorbax 300B-C18-5  µm chip, 43  ×  0.075-mm 
analytical column and 40 nL enrichment column, Agi-
lent Technologies). The system was controlled by Mass 
Hunter Software (v4.0 Agilent Technologies). Theo-
retical SRM transitions were designed using Skyline 
(v.1.1.0.2905) and peptide specificity was confirmed by 
protein blast. Samples were analyzed in duplicate.
Statistical methods
Nonparametric Kruskal–Wallis test with Dunn’s multiple 
comparisons post-test or nonparametric Mann–Whit-
ney, when only two groups are compared (progressors 
and non-progressors), were applied by means of Graph-
Pad Prism 6 (version 6.01) software to calculate sta-
tistically significant differences of the values between 
different groups. We applied the ROUT method to detect 
outliers based on the false discovery rate (FDR), setting 
Q value to 5 %. Receiver operating characteristic (ROC) 
curves were generated using GraphPad Prism 6 software 
(confidence level 95 %).
Results
In Fig.  1, a schematic workflow summarizes the whole 
study. We first investigate most significant molecular 
changes in urine in response to different albuminuria 
progression affecting hypertensive patients chronically 
RAS suppressed according to groups division detailed in 
methods section: C, N, dnHA, MHA (Tables 1 , 2, Addi-
tional file 1: Tables S1 and S2).
One-way ANOVA revealed six proteins significantly 
altered: α-1-B glycoprotein, α-1 antitrypsin (AAT or 
Table 1 Baseline patients’ characteristics used in  the dis-
covery phase
Values expressed as mean ± SD or percentages (%)
BMI body mass index, HDL high‑density lipoprotein cholesterol, LDL low‑density 
lipoprotein cholesterol, N normoalbuminuria, dnHA de novo high albuminuria, 
MHA maintained high albuminuria
N (n = 5) dnHA (n = 5) MHA (n = 5) P value
Age (years) 58 ± 7 58 ± 7 62 ± 5 0.463
Sex (male), % 60 60 60 >0.999
BMI (kg/m2) 30 ± 3 29 ± 1 28 ± 4 0.650
Current smoking, % 0 40 20 0.725
Total cholesterol 
(mg/dl)
188 ± 32 157 ± 15 175 ± 18 0.159
Triglycerides (mg/dl) 114 ± 43 112 ± 68 90 ± 27 0.765
HDL cholesterol (mg/
dl)
49 ± 12 51 ± 23 58 ± 12 0.497
LDL cholesterol (mg/
dl)
116 ± 34 83 ± 13 99 ± 12 0.150
Glycaemic (mg/dl) 91 ± 11 101 ± 7 92 ± 8 0.190
Uric acid (mg/dl) 5.6 ± 1.7 6.1 ± 1.8 4.6 ± 1.2 0.330
Creatinine clearance 
rate (mg/ml)
87 ± 24 112 ± 61 89 ± 28 0.876
eGFR (ml/
min/1.73 m2)
83 ± 10 87 ± 28 88 ± 17 0.536
Systolic blood pres‑
sure (mmHg)
132 ± 16 138 ± 8 126 ± 15 0.390
Diastolic blood pres‑
sure (mmHg)
84 ± 14 83 ± 10 81 ± 7 0.869
ACR (mg/g) 3.8 ± 1.7 74 ± 33 75 ± 90 0.001
Diabetes mellitus, % 0 0 0 >0.999
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SERPINA1), tetranectin (TNA or CLEC3B), CD59 
glycoprotein (CD59), protein AMBP and zinc-α-2-
glycoprotein. Table  3 shows trends observed for inter-
groups comparisons, where arrows reflect increase or 
diminish in the group located in the upper part of the 
ratio. Further details can be found in Additional file  1: 
Table S3 and a representative image of 2D-DIGE gel is 
shown in Additional file  1: Figure S1. These initial data 
composed a training set of molecular changes taking 
place in urine with different responses to hypertension 
and albuminuria progression. Principal component anal-
ysis (PCA) showed perfect grouping of individual urines 
according to healthy condition (C), hypertension without 
albuminuria (N), dnHA or MHA. Interestingly, individu-
als with progressing albuminuria (dnHA) are those most 
separated from the normoalbuminuria status, as corre-
sponds to such unstable situation (Additional file 1: Fig-
ure S2).
An adequate validation of the previous findings was 
accomplished by a mass spectrometry-based approach 
in the urine from a new cohort of 108 individuals, to 
confirm previous data and define a molecular finger-
print most strongly associated to hypertension and albu-
minuria progression. Molecular alterations previously 
found were confirmed for CD59, AAT and TNA (Fig. 2). 
CD59 glycoprotein and AAT showed an altered response 
already in those individuals who developed dnHA (CD59 
decreases and AAT increases) who, according to these 
two proteins, behave as patients with MHA. Differently, 
TNA shows a decreasing trend in response to hyper-
tension condition. ROC curves are shown for the three 
proteins (Fig.  2). CD59 and AAT show good sensitivity 
and selectivity (AUC  =  0.888 and 0.819, respectively) 
in classifying normoalbuminuric from high albumi-
nuric (de novo or maintained). Tetranectin allows dis-
criminating between control and hypertensive subjects 
(AUC = 0.732).
It is worthwhile to note that discovery of novel poten-
tial markers associated to albuminuria progression in 
chronically RAS suppressed patients was approached 
including, exclusively, non-diabetic patients. The num-
ber of recruited individuals was highly increased in the 
validation phase, including 36  % of diabetic subjects. 
However, no significant differences were found attributed 
to the diabetic condition as can be seen in Fig.  3, apart 
from a slightly more pronounced behavior towards MHA 
observed for CD59 in diabetic dnHA.
To further evaluate these proteins as predictors of high 
albuminuria development, we performed a prospec-
tive study. A sub-group of those hypertensive patients, 
who were classified as normoalbuminuric during urine 
sampling for the study, were clinically followed up for at 
least 1 year from urine sampling (when all them showed 
normal albuminuria values). From 37 monitored patients 
25 remained as normoalbuminuric, meanwhile 12 pro-
gressed to dnHA (observed increase in at least 10 units 
of ACR). In Fig.  4a–c, albuminuria evolution for stable 
and progressed individuals can be seen, showing similar 
Table 2 Baseline patients’ characteristics used as confirmation cohort
Values expressed as mean ± SD or percentages (%)
BMI body mass index, HDL high‑density lipoprotein cholesterol, LDL low‑density lipoprotein cholesterol, N normoalbuminuria, dnHA de novo high albuminuria, MHA 
maintained high albuminuria
N (n = 47) dnHA (n = 20) MHA (n = 23) P value
Age (years) 65 ± 11 69 ± 7 65 ± 12 0.382
Sex (male), % 34 70 61 0.012
BMI (kg/m2) 31 ± 5 30 ± 4 31 ± 5 0.796
Current smoking, % 13 15 13 0.969
Total cholesterol (mg/dl) 186 ± 29 166 ± 27 170 ± 31 0.035
Triglycerides (mg/dl) 119 ± 53 130 ± 70 139 ± 74 0.488
HDL cholesterol (mg/dl) 56 ± 13 51 ± 9 44 ± 12 0.0003
LDL cholesterol (mg/dl) 106 ± 28 90 ± 19 100 ± 24 0.088
Glycaemic (mg/dl) 118 ± 42 123 ± 26 119 ± 34 0.387
Uric acid (mg/dl) 4.9 ± 1.5 6.3 ± 1.5 6.9 ± 1.7 <0.0001
Creatinine clearance rate (mg/ml) 101 ± 40 97 ± 47 76 ± 41 0.138
eGFR (ml/min/1.73 m2) 81 ± 18 68 ± 19 64 ± 29 0.024
Systolic blood pressure (mmHg) 138 ± 18 139 ± 22 140 ± 28 0.975
Diastolic blood pressure (mmHg) 81 ± 11 81 ± 11 82 ± 17 0.993
ACR (mg/g) 11 ± 13 211 ± 388 662 ± 910 <0.0001
Diabetes mellitus, % 32 60 52 0.066
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values at the time of the study for all them, independently 
of their individual progression. When CD59 and AAT 
protein levels were measured in urine collected when 
no differences were observed in albuminuria, significant 
variation for both proteins were already detected, serving 
as predictors of future albuminuria evolution (Fig. 4d, e).
Discussion
High albuminuria is a known predictor of increased 
cardiovascular risk and future cardiovascular events [4, 
27]. As such, albuminuria has to be considered more 
as a marker of damage than as a risk factor [28]. Recent 
studies in hypertensive individuals with low-moderate 
105 HTA paents












EARLY RESPONDERS TO 
ALBUMINURIA 
DEVELOPMENT
PREDICTORS?Analysis of responder proteins in urine
from NORMOalbuminurics who will
progress or not in 1 year
Fig. 1 Schematic view of workflow. HTA hypertensive; DM diabetes mellitus; N normoalbuminuric; dnHA de novo high albuminuria; MHA man‑
tained high albuminuria; DIGE differential gel electrophoresis; LC‑MS/MS liquid chromatography mass spectrometry in tandem
Table 3 Proteins significantly altered (DIGE, discovery phase) in response to different albuminuria development or pro-
gression
Arrows reflect increase or diminish in the group located in the upper part of the ratio




N/C dnHA/C MHA/C dnHA/N MHA/N MHA/dnHA 1‑ANOVA
α‑1‑beta glycoprotein A1BG P04217 ↑ ↑ ↑ ↑ ↑ ↓ 0.00042
α‑1‑antitrypsin AAT P01009 ↓ ↑ ↑ ↑ ↑ ↓ 0.018
Tetranectin TNA P05452 ↑ ↓ ↓ ↓ ↓ ↑ 0.033
AMBP protein AMBP P02760 ↓ ↓ ↓ ↓ ↑ ↑ 0.012
CD59 glycoprotein CD59 P13987 ↑ ↓ ↓ ↓ ↓ ↑ 0.0022
Zinc‑α2 glycoprotein AZGP1 P25311 ↑ ↑ ↑ ↑ ↑ ↓ 0.016
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CV risk showed that the presence of increased albumin 
excretion at baseline or de novo development of albu-
minuria during follow-up is linked to a higher CV risk 
independently of other CV risk factors [3, 8]. Renin-angi-
otensin system blockade is the most effective therapeutic 
approach to treat albuminuria with a double aim of con-
trolling BP and preventing or diminishing albuminuria. 
However, regression of albumin excretion in response to 
treatment does not necessarily imply improved CV prog-
nosis [29–31]. In fact the decrease in albuminuria needs 
to be superior to 50  % in order to see an improvement 
in prognosis [32]. Hypertension is associated with end-
organ damage, particularly affecting heart, vessels and 
kidneys, and evidence of organ damage implies signifi-
cant worsening of CV prognosis even in the presence of 
an apparently moderate global CV risk calculated accord-
ing to SCORE [33]. Albuminuria is partially a conse-
quence of high blood pressure but also other factors such 
as systemic inflammation and endothelial dysfunction 
participate in its appearance as well as on the progres-
sive decay in glomerular filtration rate [34]. Amelioration 
of the damage leading to the development of albumi-
nuria and other forms of target organ damage does not 
necessarily translate into a reduction in CV risk, even so 
assessment of end-organ damage is totally required in 
hypertensives because it allows a more adequate adjust-
ment of individual therapeutic intervention [29].
In previous studies from our group, we showed new 
onset of albuminuria in RAS suppressed hypertensives 
in 16.1 % of cases. Alterations at protein level in urine in 
response to hypertension and salt sensitivity have been 
reported [35]. In this work we aimed the identification 
of molecular indicators in urine linked to albuminuria 
development, particularly in non-diabetic hyperten-
sives under chronic RAS suppression. Pursuing an early 
management aimed to prevent negative progression 
and irreversible damage, identified responder proteins 
were also investigated in urine from normoalbuminuric 
patients. We identified a urine molecular panel of pro-
teins responding differently to albuminuria development 
in our patients: CD59, AAT and TNA. CD59 and AAT 
already showed altered levels in urine in patients devel-
oping high albuminuria during the follow-up before the 
rise in the urinary protein took place, thus serving as 
predictors of the progression to high albuminuria. CD59 
was found to be down-regulated in urine before and after 
Fig. 2 CD59 (1a, 2a), AAT (1b, 2b) and TNA (1c, 2c) urinary response in healthy and hypertensive patients chronically RAS suppressed at different 
stages of albuminuria progression. Graphs show normalized peak area from SRM‑LC‑MS/MS data. ROC curves evaluate response to albuminuria 
condition (CD59 and AAT) or hypertension (TNA)
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the rise in albumin excretion in urine. CD59 inhibits the 
membrane attack complex (MAC) to protect cells in an 
inflammatory scenario. CD59 and decay accelerating fac-
tor (DAF) are synthesized by mesangial and epithelial 
cells, and complement activation translates into higher 
levels of both in a number of renal diseases, among them 
those with glomerular injury [36, 37]. However this 
increment did not occur in other renal diseases particu-
larly those with tubulo-interstitial damage and a similar 
situation could happen in our patients [36]. Interestingly, 
a slight increase in blood pressure was observed in CD59 
knockout mice [38]. In agreement, a reduced expression 
of CD59 in endothelial cells from hypertensive patients 
has been described, suggesting a potential role in devel-
opment of hypertension and increased CV risk [39]. 
Similarly a diminished urinary CD59 has been found in 
diabetics (normo and microalbuminuric) potentially con-
tributing to the increased CV risk in these patients [15]. 
In our study, CD59 showed low urinary levels in patients 
developing de novo albuminuria. The decrease was more 
pronounced in diabetics. Additionally, urinary CD59 was 
shown to differentiate those hypertensive patients with 
normal albuminuria who will negatively progress. Thus, 
these observations suggest that decreased urinary levels 
of CD59 can be considered as an early indicator of vascu-
lar damage and progression of atherosclerosis in chroni-
cally RAS suppressed hypertensives [40, 41].
AAT is an inflammation-sensitive plasma protein (ISP) 
found increased in urine of individuals with diabetic 
nephropathy [42, 43], in diabetics with normo, micro 
or macroalbuminuria [44, 45] and in serum of obese 
individuals with metabolic syndrome [46], pointing to 
a role for this protein in diabetic complications. AAT is 
also increased in urine from patients with essential and 
secondary hypertension, but without a correlation with 
albumin excretion in urine, which supports the idea of 
glomerular filtration and AAT local production in dam-
aged kidney as confluencing mechanisms responsible 
for increased levels in urine [47]. Our study goes a step 
further, non-diabetics show increased urinary AAT lev-
els in patients developing de novo albuminuria as well as 
in those with maintained albuminuria. More importantly, 
increased level in urine from normoalbuminurics enables 
to predict a negative progression. Thus, if albuminuria 
is considered an indicator of (renal) end-organ damage, 
we hypothesize that the increase in AAT observed in 
Fig. 3 Effect of diabetes mellitus on urinary CD59 (1a, 2a), AAT (1b, 2b) and TNA (1c, 2c). dnHA diabetic patients show CD59 levels closer to those 
observed for individuals with MHA
Page 8 of 11Gonzalez‑Calero et al. Cardiovasc Diabetol  (2016) 15:8 
normoalbuminuric hypertensives with negative progno-
sis (albuminuria development) can be considered as an 
earlier evidence, supporting the idea of local synthesis in 
response to inflammation.
The existence of a cross-talk between cardiovascular 
and renal systems, accompanied by activation of the coag-
ulation system, increased inflammation and altered auto-
immune reactivity has been shown [48–51]. In particular, 
AAT inhibits activated protein C and plasminogen activa-
tor (PA) which promotes the conversion of plasminogen 
to plasmin which in turn acts to degrade fibrin. Tetranec-
tin also enhances plasminogen activation and plasma 
TNA levels have been inversely associated with coronary 
artery disease [52]. Increased levels in AAT and decreased 
levels in TNA in response to albuminuria point in the 
same direction, taking in an impairment of the regula-
tion of the anticoagulation system and in agreement with 
a potential therapeutical intervention over  plasminogen 
activator inhibitor (PAI-1) in hypertensives [53].
These altered responses point in one direction, linking 
vascular dysfunction and kidney disease (Fig.  5) [54]. 
Molecular alterations found here not only respond to 
high albuminuria clinical condition, but interestingly, 
they are already altered in normoalbuminuric patients 
chronically treated who will further progress to high 
albuminuria. Thus, molecular disorders related to vas-
cular dysfunction, atherosclerosis progression and car-
diovascular risk are already taking place at earlier stages 
when albuminuria is still in the normal range.
This study accomplishes the requirements for a 
proteomics study in urine with a small initial cohort 
of non-diabetic patients for the discovery phase. The 
group used in the validation cohort was significantly 















































Fig. 4 CD59 and AAT predict progression of albuminuria in normoalbuminuric patients. Albuminuria was evaluated at sampling and at least 1 year 
later and individuals were classified as non‑progressors or progressors (a, b, c). Levels of CD59 and AAT in urine when those individuals were nor‑
moalbuminuric can already distinguish both groups, anticipating future development or not of albuminuria (d, e)
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non-diabetic individuals. However, as we have demon-
strated here, the presence of diabetes did not signifi-
cantly influence our findings.
Conclusions
Our data were obtained in hypertensive patients on chronic 
RAS suppression. CD59 and AAT proteins are signifi-
cantly altered in hypertensive patients (diabetics and non-
diabetics) developing albuminuria de novo, despite being 
treated. Additionally, CD59 and AAT are able to predict in 
normoalbuminuric individuals who will develop albuminu-
ria in the future. These findings contribute to early identi-
fication of patients at risk of developing albuminuria even 
when this classical predictor is still in the normal range, 
that is patients in whom cardiovascular and renal disease 
progresses despite RAS suppression. Our data set the basis 
for a novel strategy towards a prompt and more efficient 
therapeutic intervention with better outcome, i.e. identify-
ing patients at risk of developing albuminuria and in whom 
enhancement of RAS blockade, probably by using a miner-
alocorticoid receptor antagonist, may be indicated.
Additional file
Additional file 1. Figure S1. Representative image of 2D‑DIGE gel. 
Figure S2. Principal component analysis (PCA) graph. Each dot represents 
a urine sample used in the discovery phase (DIGE analysis). Table S1. 
Baseline medication for those patients including in the discovery phase. 
Data are expressed as percentages (%). ACEi: angiotensin converting 
enzyme inhibitors; ARB: angiotensin receptor blockers. N: normoal‑
buminuria; dnHA: de novo high albuminuria; MHA: maintained high 
albuminuria. Table S2. Baseline medication for those patients including 
in the validation phase. Data are expressed as percentages (%). ACEi: 
angiotensin converting enzyme inhibitors; ARB: angiotensin receptor 
blockers. N: normoalbuminuria; dnHA: de novo high albuminuria; MHA: 
maintained high albuminuria. Table S3. Proteins identifiedper gel spot 
with significant alteration (one‑way ANOVA). The table shows the number 
of unique peptides identified, % sequence coverage and trends observed 
for each protein between compared groups (increase or decrease in the 
group located in the upper part of the ratio). Two spots contain a mixture 
of two proteins each, thus changes in expression forthose spots cannot 
be attributed to any of the two proteins initially. When one protein was 
identified in several spots, observed variations between groups followed 
the same trend (e.g. CD59 and alpha‑1‑antitrypsin). Table S4. SRM‑LCMS/
MS analysis conditions for those proteins confirmed in the validation 
phase with statistical signification (ANOVA <0.0001). Details of protein 
transitions (precursor and fragments masses), collision energy and peptide 
sequences are included.
Fig. 5 Main alterations in response to albuminuria progression point to inflammation and coagulation disorders as main biological pathways 
involved. Differences observed already in normoalbuminuria condition reveal subjacent mechanisms associated with cardiovascular risk taking 
place already in asymptomatic stages
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